<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634777</url>
  </required_header>
  <id_info>
    <org_study_id>PET N GETTEC</org_study_id>
    <nct_id>NCT00634777</nct_id>
  </id_info>
  <brief_title>Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma</brief_title>
  <acronym>pet</acronym>
  <official_title>Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with advanced head and neck squamous cell carcinoma (HNSCC) may benefit from&#xD;
      organ-preservation treatment based on combination of chemotherapy and radiotherapy without&#xD;
      compromising disease-free and overall survival. In patients with initially advanced regional&#xD;
      disease, there is controversy about the place of routine planned lymph node neck dissection&#xD;
      after chemoradiotherapy, especially in responding patients without clinically invaded&#xD;
      residual lymph nodes. There is uncertainty about the lymph nodes status after chemoradiation&#xD;
      because the structural imaging modalities (CT, MRI) lack sensitivity and specificity : small&#xD;
      positive lymph nodes are not detected, and residual large lymph nodes can be sterilized ( &quot;&#xD;
      ghosts nodes &quot; with no sign of viable tumor cells at histopathology). Despite the absence of&#xD;
      evidence based on prospective study, in numerous institutions currently, head and neck&#xD;
      surgeons are quite reluctant to operate on for neck dissection patients with a complete&#xD;
      clinical and radiological response following chemoradiation.&#xD;
&#xD;
      Metabolic imaging of tumors using PET and the glucose analog FDG has proven effective in head&#xD;
      and neck SCC, especially after treatment to differentiate disease progression from&#xD;
      radiation-induced inflammation.1 Several studies have shown that the metabolic response could&#xD;
      predict the presence or absence of residual tumor cells in the primary tumor as well as the&#xD;
      probability of relapse .2-4 Conflicting results have been reported on the use of PET to&#xD;
      predict the pathological nodal status after chemoradiation, with negative predictive values&#xD;
      ranging from 14 % to 100 %.5,6 Discrepancies observed might be due to the fact that PET was&#xD;
      performed at variable time points after the end of radiotherapy. Ideally, PET should be&#xD;
      performed as late as possible so that tumor regrowth can begin and become detectable,&#xD;
      increasing the sensitivity of the procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - The primary objective is to assess the negative predictive value (NPV) of PET as a single&#xD;
      examination in correctly predicting the absence of remaining invaded lymph nodes after&#xD;
      chemoradiotherapy for advanced HNSCC.&#xD;
&#xD;
      Secondary objectives include :&#xD;
&#xD;
        -  The evaluation of the suitability of a wait and see approach without neck dissection in&#xD;
           patients considered as complete responders ( based on clinical evaluation and imaging&#xD;
           assessment including PET : all these diagnosis tools should be negative to consider a&#xD;
           patient as a complete responder); this suitability will be estimated using the negative&#xD;
           predictive value of the overall assessment of a complete response including PET-FDG but&#xD;
           also the clinical evaluation and imaging.&#xD;
&#xD;
        -  The evaluation of the ability of PET-FDG to correctly predict remaining pathologically&#xD;
           invaded lymph nodes (PPV) after chemoradiotherapy for advanced HNSCC in patients with a&#xD;
           postchemoradiation positive PET a (and who will therefore be considered with less than a&#xD;
           complete regional or locoregional response and who will undergo at least neck&#xD;
           dissection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of PET scan in evaluation of patient with HNSCC regionally advanced</measure>
    <time_frame>12 weeks after chemoradiation</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">239</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pet scan</intervention_name>
    <description>pet scan</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-proven HNSCC&#xD;
&#xD;
          -  Clinical stage: unpreviously treated T1-T4 oral cavity, oropharynx, hypopharynx,&#xD;
             larynx&#xD;
&#xD;
          -  Only patients suitable for at least a neck dissection after chemoradiotherapy will be&#xD;
             included. Consequently, inclusion criteria are thus : T1-T4 , N1 N2a, N2b N2c N3 M0.&#xD;
&#xD;
          -  Patient scheduled for an organ preservation treatment protocol based on concomitant&#xD;
             chemoradiation (induction chemotherapy is allowed if this approach is followed by&#xD;
             concomitant chemoradiation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Hamoir, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cliniques Universitaires Saint-Luc, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guy Andry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jules Bordet, Brussels</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Hamoir, MD</last_name>
    <phone>+3227641974</phone>
    <email>marc.hamoir@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Schmitz, MD</last_name>
    <phone>+32427641976</phone>
    <email>schmitz_sany@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liza Nguyen Gia, MSc</last_name>
      <phone>+3227641274</phone>
      <email>liza.nguyen-gia@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Schmitz, MD</last_name>
      <phone>+3227641976</phone>
      <email>schmitz_sany@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Hamoir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Max Lonneux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>March 6, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <last_update_submitted>July 19, 2011</last_update_submitted>
  <last_update_submitted_qc>July 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof Hamoir</name_title>
    <organization>Cliniques Universitaires Saint-Luc</organization>
  </responsible_party>
  <keyword>HNSCC biopsy-proven</keyword>
  <keyword>T1-T4 oral cavity oropharynx hypopharynx larynx</keyword>
  <keyword>N+ scheduled for an organ preservation treatment protocol based on concomitant</keyword>
  <keyword>chemoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

